Showing results (11-20 of 133) with videos related to

Sort By:
Pageof 14
Current Cancer Drug Targets|February 20, 2007
Indoleamine 2,3-dioxygenase in immune suppression and cancerAlexander J Muller, George C Prendergast
Cancer Research|April 7, 2007
Cancer immunologists and cancer biologists: why we didn't talk then but need to nowGeorge C Prendergast, Elizabeth M Jaffee
Cancer Research|September 17, 2005
Marrying immunotherapy with chemotherapy: why say IDO?Alexander J Muller, George C Prendergast
Plos One|November 2, 2022
Bin1 targeted immunotherapy alters the status of the enteric neurons and the microbiome during ulcerative colitis treatmentSunil Thomas, Giancarlo Mercogliano, George C Prendergast
Methods in Enzymology|November 16, 2019
Reliable detection of indoleamine 2,3 dioxygenase-1 in murine cells and tissuesSunil Thomas, Lisa Laury-Kleintop, George C Prendergast
Cancer Biology & Therapy|July 25, 2003
Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoBUma Kamasani, Ai-xue Liu, George C Prendergast
Cancer Research|January 26, 2002
Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expressionBin Zhang, George C Prendergast, Robert G Fenton
Cancer Journal (Sudbury, Mass.)|January 24, 2023
A Brief Overview of Cancer VaccinesAlexander J Muller, Sunil Thomas, George C Prendergast
The American Journal of Pathology|March 16, 2010
Towards a genetic definition of cancer-associated inflammation: role of the IDO pathwayGeorge C Prendergast, Richard Metz, Alexander J Muller
Pageof 14